1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Chongqing Pharscin Pharmaceutical Co., Ltd.

Chongqing Pharscin Pharmaceutical Co., Ltd.

002907.SZ
Chongqing Pharscin Pharmaceutical Co., Ltd.CN flagShenzhen Stock Exchange
13.24
CNY
-0.50
- -
5.53BMarket Cap
Chongqing Pharscin Pharmaceutical Co., Ltd.
002907.SZ
(Shenzhen Stock Exchange)

Recent

price

13.24

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
1.3
1.53
1.61
1.76
2.1
2.2
2.11
1.95
1.66
1.85
1.98
1.91
Revenue per Share
- -
- -
0.21
0.27
0.31
0.34
0.42
0.3
0.23
0.24
0.08
0.18
0.16
0.2
Basic EPS, GAAP
- -
- -
0.14
0.11
0.11
-0.01
- -
0.17
0.07
-0.12
0.3
0.35
0.11
-0.03
Free Cash Flow per Basic Share
- -
- -
0.01
0.01
- -
0.07
0.04
0.05
0.03
0.06
0.07
0.08
0.09
0.03
Dividend per Share
- -
- -
0.94
1.23
1.59
1.7
2.05
2.27
2.45
2.65
2.55
2.63
2.68
2.71
Book Value per Share
- -
- -
0.84
1.07
1.76
1.88
2.48
2.77
2.91
3.71
3.49
3.6
3.52
3.5
Tangible Book Value per Share
- -
- -
360
360
367
400
400
401
401
403
418
418
417
418
Basic Weighted Avg Shares
347
426
469
552
592
703
842
882
846
785
692
775
827
799
Sales/Revenue/Turnover
9.47
14.62
16.6
17.84
22.14
22.5
23.88
15.7
12.6
15.15
5.95
10.98
8.42
10.65
Operating Margin (%)
- -
14
17
19
21
22
24
47
70
75
82
87
88
- -
Depreciation Expense
29
59
74
96
112
137
170
119
92
98
33
77
65
83
Net Income, GAAP
22.73
15.02
16.22
15.64
15.4
14.63
14.27
13.03
11.25
9.09
23.59
17.88
28.72
16.84
Effective Tax Rate (%)
8.33
13.8
15.73
17.35
18.91
19.53
20.16
13.51
10.85
12.53
4.73
9.9
7.87
10.45
Profit Margin (%)
49
102
137
206
403
330
568
633
687
746
706
819
864
832
Working Capital
- -
- -
- -
- -
- -
5
220
236
251
- -
- -
- -
3
- -
LT Debt
241
300
366
461
720
829
1,071
1,182
1,266
1,610
1,618
1,660
1,707
1,709
Total Equity
- -
14.2
15.73
17.97
17.81
16.68
15.83
8.85
6.45
6.93
1.95
4.27
2.9
4.17
Return on Invested Capital (%)
- -
18.34
21.12
22.51
20.71
20.81
20.08
12.2
9.03
9.69
3.13
7.05
6.59
7.26
Return on Capital (%)
- -
23.78
24.17
24.5
21.78
21.72
22.63
13.77
9.7
9.6
3.06
7.09
5.87
7.5
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
- -
- -
38
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
418
418
418
Market Capitalization
5,430
5,560
6,956

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,031
1,091
1,089
Cash, Cash Equivalents & STI
577
548
526
Accounts Receivable, Net
175
221
212
Inventories
140
128
121
Total Current Liabilities
212
210
257
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
38
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.71%
8.05%
2.84%
Free Cash Flow
422.16%
-152.09%
-67.25%
Net Income, GAAP
10%
7.39%
-15.17%
Sales/Revenue/Turnover
6.37%
-0.89%
6.75%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
228
189
196
161
775
2025
239
203
201
- -
827
2026
212
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.1
- -
- -
- -
0.18
2025
0.1
- -
- -
- -
0.16
2026
0.08
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.08
2025
- -
- -
- -
- -
0.09
2026
- -
- -
- -
- -
- -
Similar Companies
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHEZF)
Fagron N.V. (ARSUF)
TerrAscend Corp. (TRSSF)
Bright Green Corporation (BGXX)
DURECT Corporation (DRRX)
The Now Corporation (NWPN)
Business
Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) is a China-based company principally engaged in the research, development, production and sale of pharmaceuticals, focusing on treatments for central nervous system disorders, digestive diseases, otolaryngology conditions, oncology, cardiovascular and cerebrovascular ailments; it offers tablets including tangerine ice plum tablets, Weidimei magnesium aluminum carbonate chewable tablets and cilostazol tablets; powders, granules such as Bawei Qilong granules; hard and soft capsules including Liuwei Anshen capsules, Duliang softgels, cholesterol softgels and orlistat capsules; powder injections, freeze-dried powder injections; small-volume injections such as injectable gabelate mesylate, omeprazole sodium, sodium ferulinate and troxerutin injections; active pharmaceutical ingredients through synthesis; and botanical drug extractions incorporating traditional Chinese medicine technologies. Founded in 1996 and headquartered in Rongchang District, Chongqing, the company operates 11 to 22 advanced production lines compliant with GMP standards, including automated intelligent systems for extraction of thermosensitive active ingredients, powder transmission and soft capsule production; it maintains a marketing network covering 31 provinces in China with products reaching over 4000 hospitals and is expanding internationally. Subsidiaries include Chongqing Pharscin Medicine Co., Ltd. for pharmaceutical distribution, Chongqing Pharscin Pharmacy Retail Chain Co., Ltd. for retail and Chongqing Pharscin Biotech Co., Ltd. for biotechnology research, supporting an integrated model across pharmaceutical industry, commerce and retail segments. The company holds 68 drug varieties with 49 in China's National Medical Insurance catalog and 46 domestic patents, having undertaken 98 national and provincial R&D projects including "Eleventh Five-Year" and "Twelfth Five-Year" Major New Drug developments; it pursues first-in-class innovative drugs via platforms for cancer driver gene screening, medicinal chemistry and drug metabolism pharmacokinetics. Recent developments encompass expansion of its distribution network through partnerships with over 200 new regional distributors since 2021; completion of shareholding reductions by controlling shareholders and senior management in 2025; updates to drug production licenses and successful GMP compliance checks; industrial and commercial registration changes for holding subsidiaries; and advancements in 5G-enabled intelligent manufacturing as a national high-tech enterprise.